Most typhoid cases in Uganda occur in children younger than 15 years old.

Drug-resistant typhoid strains are a growing problem in Uganda, regionally, and across the globe.

During an outbreak in Bundibugyo and Kasese Districts from 2008 to 2011, multidrug-resistant strains increased from just 5% of isolates in 2009 to 83% of isolates in 2011.

As drug-resistant typhoid becomes more common, it will become more difficult to treat and force the use of more expensive and less readily-available treatment options.

Typhoid incidence per 100,000 – 2019
- <50
- 50-100
- 101-300

While typhoid is rarely fatal, the recovery is long and difficult. The disease takes time, money, and productivity from those infected and their families and is associated with numerous long-term complications.
Typhoid conjugate vaccines (TCVs) in Uganda

The World Health Organization (WHO) recommends the introduction of prequalified TCVs be prioritized in countries with a high burden of typhoid disease or a high burden of drug-resistant typhoid. Gavi, the Vaccine Alliance support for introduction is available now. TCVs:

- Are highly effective and safe for children as young as 6 months of age;
- Require a single dose to prevent 79-85% of typhoid cases in children;
- Offer strong protection for at least 4 years; and
- Can be co-administered with measles-rubella and meningococcal A vaccines.⁵

Findings from an economic analysis predict that, even in the absence of a Gavi subsidy, a catch-up campaign with TCV could be cost-effective in Uganda.⁶

Let’s Take on Typhoid in Uganda

- Typhoid is endemic in Uganda, with more than 41,000 cases per year.
- Uganda’s burden of typhoid is most heavily borne by children under 15 years of age.
- Data show an increase in drug-resistant typhoid in Uganda, regionally, and globally.
- TCVs are safe, effective, and WHO-recommended for routine immunization as part of a cost-effective, integrated approach to typhoid prevention and control alongside safe water, sanitation, and hygiene interventions.
- Gavi support for TCV introduction is available now.